David C Shonka1, Alan Ho2, Ashish V Chintakuntlawar3, Jessica L Geiger4, Jong C Park5, Nagashree Seetharamu6, Sina Jasim7, Amr H Abdelhamid Ahmed8, Keith C Bible3, Marcia S Brose9, Maria E Cabanillas10, Kirsten Dabekaussen11, Louise Davies12, Dora Dias-Santagata13, James A Fagin14, William C Faquin13, Ronald A Ghossein15, Raj K Gopal5, Akira Miyauchi16, Yuri E Nikiforov17, Matthew D Ringel18, Bruce Robinson19, Mabel M Ryder20, Eric J Sherman21, Peter M Sadow13, Jennifer J Shin22, Brendan C Stack23, R Michael Tuttle14, Lori J Wirth5, Mark E Zafereo24, Gregory W Randolph8. 1. Department of Otolaryngology - Head and Neck Surgery, University of Virginia, Charlottesville, Virginia, USA. 2. Department of Hematology and Medical Oncology, Solid Tumor Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 3. Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA. 4. Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA. 5. Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. 6. Division of Hematology-Oncology, Donald and Barbara Zucker School of Medicine at Hofstra University, New Hyde Park, New York, USA. 7. Division of Endocrinology, Metabolism and Lipid Research, Department of Internal Medicine, School of Medicine, Washington University in St. Louis, Saint Louis, Missouri, USA. 8. Department of Otolaryngology - Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA. 9. Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 10. Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. 11. Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 12. Department of Surgery, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA. 13. Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 14. Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 15. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 16. Department of Surgery, Kuma Hospital, Kobe, Japan. 17. Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 18. Division of Endocrinology, Diabetes, and Metabolism, The Ohio State University Medical Center, Columbus, Ohio, USA. 19. Northern Clinical School, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia. 20. Division of Endocrinology, Diabetes, Metabolism, & Nutrition, Mayo Clinic, Rochester, Minnesota, USA. 21. Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 22. Department of Otolaryngology - Head and Neck Surgery, Center for Surgery and Public Health, Harvard Medical School, Boston, Massachusetts, USA. 23. Department of Otolaryngology - Head and Neck Surgery, Southern Illinois University School of Medicine, Springfield, Illinois, USA. 24. Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Abstract
BACKGROUND: The development of systemic treatment options leveraging the molecular landscape of advanced thyroid cancer is a burgeoning field. This is a multidisciplinary evidence-based statement on the definition of advanced thyroid cancer and its targeted systemic treatment. METHODS: An expert panel was assembled, a literature review was conducted, and best practice statements were developed. The modified Delphi method was applied to assess the degree of consensus for the statements developed by the author panel. RESULTS: A review of the current understanding of thyroid oncogenesis at a molecular level is presented and characteristics of advanced thyroid cancer are defined. Twenty statements in topics including the multidisciplinary management, molecular evaluation, and targeted systemic treatment of advanced thyroid cancer are provided. CONCLUSIONS: With the growth in targeted treatment options for thyroid cancer, a consensus definition of advanced disease and statements regarding the utility of molecular testing and available targeted systemic therapy is warranted.
BACKGROUND: The development of systemic treatment options leveraging the molecular landscape of advanced thyroid cancer is a burgeoning field. This is a multidisciplinary evidence-based statement on the definition of advanced thyroid cancer and its targeted systemic treatment. METHODS: An expert panel was assembled, a literature review was conducted, and best practice statements were developed. The modified Delphi method was applied to assess the degree of consensus for the statements developed by the author panel. RESULTS: A review of the current understanding of thyroid oncogenesis at a molecular level is presented and characteristics of advanced thyroid cancer are defined. Twenty statements in topics including the multidisciplinary management, molecular evaluation, and targeted systemic treatment of advanced thyroid cancer are provided. CONCLUSIONS: With the growth in targeted treatment options for thyroid cancer, a consensus definition of advanced disease and statements regarding the utility of molecular testing and available targeted systemic therapy is warranted.
Authors: Alexander Drilon; Salvatore Siena; Sai-Hong Ignatius Ou; Manish Patel; Myung Ju Ahn; Jeeyun Lee; Todd M Bauer; Anna F Farago; Jennifer J Wheler; Stephen V Liu; Robert Doebele; Laura Giannetta; Giulio Cerea; Giovanna Marrapese; Michele Schirru; Alessio Amatu; Katia Bencardino; Laura Palmeri; Andrea Sartore-Bianchi; Angelo Vanzulli; Sara Cresta; Silvia Damian; Matteo Duca; Elena Ardini; Gang Li; Jason Christiansen; Karey Kowalski; Ann D Johnson; Rupal Patel; David Luo; Edna Chow-Maneval; Zachary Hornby; Pratik S Multani; Alice T Shaw; Filippo G De Braud Journal: Cancer Discov Date: 2017-02-09 Impact factor: 39.397
Authors: Debyani Chakravarty; Elmer Santos; Mabel Ryder; Jeffrey A Knauf; Xiao-Hui Liao; Brian L West; Gideon Bollag; Richard Kolesnick; Tin Htwe Thin; Neal Rosen; Pat Zanzonico; Steven M Larson; Samuel Refetoff; Ronald Ghossein; James A Fagin Journal: J Clin Invest Date: 2011-11-21 Impact factor: 14.808
Authors: Yoram Cohen; Mingzhao Xing; Elizabeth Mambo; Zhongmin Guo; Guogun Wu; Barry Trink; Uziel Beller; William H Westra; Paul W Ladenson; David Sidransky Journal: J Natl Cancer Inst Date: 2003-04-16 Impact factor: 13.506
Authors: Michael Rivera; Ronald A Ghossein; Heiko Schoder; Daniel Gomez; Steven M Larson; R Michael Tuttle Journal: Cancer Date: 2008-07-01 Impact factor: 6.860
Authors: Anastasios Maniakas; Ramona Dadu; Naifa L Busaidy; Jennifer R Wang; Renata Ferrarotto; Charles Lu; Michelle D Williams; G Brandon Gunn; Marie-Claude Hofmann; Gilbert Cote; Jared Sperling; Neil D Gross; Erich M Sturgis; Ryan P Goepfert; Stephen Y Lai; Maria E Cabanillas; Mark Zafereo Journal: JAMA Oncol Date: 2020-09-01 Impact factor: 31.777
Authors: Katayoon Kasaian; Sam M Wiseman; Blair A Walker; Jacqueline E Schein; Yongjun Zhao; Martin Hirst; Richard A Moore; Andrew J Mungall; Marco A Marra; Steven J M Jones Journal: BMC Cancer Date: 2015-12-18 Impact factor: 4.430